Skip to content
ClinCalc Pro
Menu
Volatile Inhalational Anaesthetic

Sevoflurane

Brand names: Ultane, Sevorane

Sevoflurane is a volatile halogenated inhalational anaesthetic agent used for the induction and maintenance of general anaesthesia in adults and children.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It produces general anaesthesia through actions on central nervous system ligand-gated ion channels, including potentiation of GABA-A receptor activity, leading to loss of consciousness.

Prescribing in practice

  • It is a recognised trigger of malignant hyperthermia in susceptible individuals, so a personal or family history must be sought and dantrolene and an emergency protocol must be available.
  • Its low pungency and rapid onset and offset make it well suited to inhalational (gas) induction, particularly in paediatric anaesthesia.
  • It causes dose-dependent respiratory and cardiovascular depression and must be delivered through a calibrated vaporiser with anaesthetic gas scavenging.

Monitoring

Monitor end-tidal anaesthetic concentration, oxygenation, ventilation, haemodynamics and temperature throughout administration.

Counselling the patient

  • This anaesthetic gas is delivered by an anaesthetist with full monitoring.
  • Tell the team about any personal or family history of serious reactions to anaesthesia.

Evidence & guidelines

Its use in induction and maintenance of anaesthesia, including paediatric gas induction, is standard practice supported by the SPC and anaesthetic guidance.

Reference: RCoA GPAS 2023; AAGBI Malignant Hyperthermia Guidelines 2020; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.